EP3886824 - COMBINED TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 19.01.2024 Database last updated on 31.08.2024 | |
Former | Request for examination was made Status updated on 03.09.2021 | ||
Former | The international publication has been made Status updated on 06.06.2020 | ||
Former | unknown Status updated on 17.01.2020 | Most recent event Tooltip | 20.06.2024 | New entry: Reply to examination report | Applicant(s) | For all designated states Fondazione Centro San Raffaele Via Olgettina, 60 20132 Milano / IT | [2021/40] | Inventor(s) | 01 /
CORTI, Angelo Via Olgettina 60 20132 Milano (MI) / IT | 02 /
FERRERI, Andrés José Maria Via Olgettina 60 20132 Milano (MI) / IT | [2021/40] | Representative(s) | Pace Napoleone, Maria, et al De Simone & Partners S.r.l. Via Vincenzo Bellini, 20 00198 Roma / IT | [N/P] |
Former [2021/40] | Turri, Elisa, et al De Simone & Partners S.r.l. Via Vincenzo Bellini, 20 00198 Roma / IT | Application number, filing date | 19832570.6 | 02.12.2019 | [2021/40] | WO2019EP83322 | Priority number, date | US201862773473P | 30.11.2018 Original published format: US 201862773473 P | [2021/40] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020109625 | Date: | 04.06.2020 | Language: | EN | [2020/23] | Type: | A1 Application with search report | No.: | EP3886824 | Date: | 06.10.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 04.06.2020 takes the place of the publication of the European patent application. | [2021/40] | Search report(s) | International search report - published on: | EP | 04.06.2020 | Classification | IPC: | A61K31/00, A61K38/19, A61K39/395, A61P35/00 | [2021/40] | CPC: |
A61K38/191 (EP,IL,US);
A61K31/475 (EP,IL,US);
A61K31/573 (EP,IL,US);
A61K31/675 (EP,IL,US);
A61K31/704 (EP,IL,US);
A61K39/3955 (EP,IL,US);
A61P35/00 (EP,IL,US);
A61K2039/505 (EP,IL,US);
A61K2039/545 (EP,IL,US);
| C-Set: |
A61K31/475, A61K2300/00 (EP);
A61K31/573, A61K2300/00 (EP);
A61K31/675, A61K2300/00 (EP);
A61K31/704, A61K2300/00 (EP); | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/40] | Title | German: | KOMBINIERTE BEHANDLUNG VON PRIMÄREM LYMPHOM DES ZENTRALNERVENSYSTEMS | [2021/40] | English: | COMBINED TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA | [2021/40] | French: | TRAITEMENT COMBINÉ DU LYMPHOME PRIMAIRE DU SYSTÈME NERVEUX CENTRAL | [2021/40] | Entry into regional phase | 21.06.2021 | National basic fee paid | 21.06.2021 | Designation fee(s) paid | 21.06.2021 | Examination fee paid | Examination procedure | 21.06.2021 | Examination requested [2021/40] | 21.06.2021 | Date on which the examining division has become responsible | 14.01.2022 | Amendment by applicant (claims and/or description) | 22.01.2024 | Despatch of a communication from the examining division (Time limit: M06) | 20.06.2024 | Reply to a communication from the examining division | Fees paid | Renewal fee | 18.11.2021 | Renewal fee patent year 03 | 21.12.2022 | Renewal fee patent year 04 | 27.12.2023 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]AU2008207357 (BIOGEN IDEC INC) [Y] 1-7 * pages 23,30 *; | [Y]EP2364995 (MOLMED SPA [IT], et al) [Y] 1-7* paragraphs [0012] , [0019] - [0022] - [0199] , [0205] *; | [Y]US2015246123 (DOSHI PARUL [US]) [Y] 1-7 * paragraphs [0013] - [0018] *; | [XY] - FERRERI ANDRES J M ET AL, "R-CHOP Preceded By Engineered Tumor Necrosis Factor (TNF) in Patients with Relapsed or Refractory (r/r) Primary CNS Lymphoma (PCNSL): Results of Antitumor Activity, Safety and Blood-Brain Barrier (BBB) Permeabilization in the "Ingrid" Phase II Trial", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (20181129), Database accession no. PREV201900317358, XP002798112 [X] 1,3-5,7 * abstract * [Y] 1-7 DOI: http://dx.doi.org/10.1182/blood-2018-99-118507 | [ ] - BLOOD, 60TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY (ASH); SAN DIEGO, CA, USA; DECEMBER 01 -04, 2018, (20181129), vol. 132, no. Suppl. 1, doi:10.1182/BLOOD-2018-99-118507, ISSN 0006-4971(print), page 1687 |